{"id":"nicodermcq","safety":{"commonSideEffects":[{"rate":"15-20","effect":"Skin irritation at patch site"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Dizziness"},{"rate":"5-10","effect":"Sleep disturbances"},{"rate":"5","effect":"Vivid dreams"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The patch provides a steady, controlled release of nicotine through the skin into the bloodstream, bypassing the need for smoking. This maintains nicotine levels to suppress cravings and withdrawal symptoms (irritability, anxiety, difficulty concentrating) while the user gradually reduces dependence. The transdermal route avoids the harmful combustion products of cigarettes while allowing behavioral modification.","oneSentence":"NicodermCQ delivers nicotine transdermally to replace nicotine from cigarettes and reduce withdrawal symptoms during smoking cessation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:34:59.687Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Smoking cessation as an aid to quit smoking"}]},"trialDetails":[{"nctId":"NCT02859142","phase":"PHASE4","title":"Varenicline Augmentation of Patch Outcomes in Heavy Drinkers' Smoking Cessation","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2018-03-29","conditions":"Smoking Cessation, Alcohol Drinking","enrollment":122},{"nctId":"NCT01048944","phase":"PHASE4","title":"Nicotine Replacement Therapy (NRT) and Bupropion Mechanisms of Effectiveness in Smokers","status":"COMPLETED","sponsor":"Southern Illinois University Carbondale","startDate":"2005-06","conditions":"Nicotine Dependence","enrollment":197},{"nctId":"NCT00894166","phase":"PHASE3","title":"Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype","status":"COMPLETED","sponsor":"Duke University","startDate":"2009-05","conditions":"Smoking Cessation","enrollment":606}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Transdermal Nicotine Patch"],"phase":"marketed","status":"active","brandName":"NicodermCQ","genericName":"NicodermCQ","companyName":"University of Chicago","companyId":"university-of-chicago","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NicodermCQ delivers nicotine transdermally to replace nicotine from cigarettes and reduce withdrawal symptoms during smoking cessation. Used for Smoking cessation as an aid to quit smoking.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}